FDA eyes new diabetes outcome measures

29 September 2016 - A recent FDA workshop brought new diabetes outcome measures to the table, focusing on patient-oriented outcome measures. ...

Read more →

U.S. FDA approves Invokamet XR (canagliflozin with metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes

21 September 2016 - Newest Invokana (canagliflozin) plus metformin treatment provides unique formulation option for first-line therapy. ...

Read more →

Sanofi provides update on new drug application for investigational once-daily fixed-ratio combination of insulin glargine and lixisenatide

19 August 2016 - Sanofi announced today that it has submitted updated information on the pen delivery device as part ...

Read more →

FDA approves Adlyxin to treat type 2 diabetes

28 July 2016 - The U.S. FDA approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along ...

Read more →

U.S. FDA expands indication for type 2 diabetes treatment Synjardy (empagliflozin/metformin hydrochloride) to include treatment-naïve adults

19 July 2016 - The U.S. FDA has approved an expanded indication for Synjardy (empagliflozin and metformin hydrochloride) tablets to include ...

Read more →

U.S. FDA approves once-daily Jentadueto XR (linagliptin and metformin hydrochloride extended release tablets) for adults with type 2 diabetes

31 May 2016 - The US FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release tablets) for the treatment ...

Read more →

U.S. FDA approves Synjardy (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes mellitus

27 August 2015 - The U.S. Food and Drug Administration (FDA) has approved Synjardy (empagliflozin with metformin hydrochloride) tablets, from Boehringer ...

Read more →